### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1. Product identifier
- **Product name**: ALECENSA® Capsules (150 mg)
- **Product code**: SAP-10156875
- **Synonyms**:
  - Alectinib Hard Capsules (150 mg)
  - Alectinib Capsules (150 mg)

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against
- Use: pharmaceutical active substance (antineoplastic)

#### 1.3. Details of the supplier of the safety data sheet
- **Enquiries**: Genentech, Inc.
  - 1 DNA Way
  - South San Francisco
  - USA-CA 94080
  - United States of America
- **Phone**: 001-(650) 225-1000
- **E-Mail**: info.sds@roche.com
- **US Chemtrec phone**: (800)-424-9300

#### 1.4. Emergency telephone number
- **Emergency telephone number**: US Chemtrec phone: (800)-424-9300

*1 referring to: Alectinib
SECTION 2: Hazards identification

Classification of the substance or mixture / Label elements

GHS Classification

Health Hazards:
- 3.5 Germ cell mutagenicity (Category 2)
  
  H341 Suspected of causing genetic defects.
- 3.7 Reproductive toxicity (Category 2)
  
  H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
- 3.9 Specific target organ toxicity - Repeated exposure (Category 2)
  
  H373 May cause damage to organs through prolonged or repeated exposure.

Signalword: Warning

Label:

Precautionary statements:
- P273 Avoid release to the environment.
- P201 Obtain special instructions before use.
- P309 + P311 IF exposed or you feel unwell: Call a POISON CENTER or doctor/physician.

Other hazards

Note - no information available

SECTION 3: Composition/information on ingredients

Characterization

Alectinib with other inactive ingredients

Ingredients

<table>
<thead>
<tr>
<th>Concentration</th>
<th>GHS-Classification (pure ingredient)</th>
</tr>
</thead>
</table>
| Alectinib hydrochloride 1256589-74-8 | 40.3 % - Combustible dust (No category), USH003  
  - Germ cell mutagenicity (Category 2), H341  
  - Reproductive toxicity (Category 2), H361fd  
  - Specific target organ toxicity - Repeated exposure (Category 2), H373 |

| Hydroxypropylmethyl cellulose 9004-65-3 | 19.2 % |
### ALECENSA® Capsules (150 mg)

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percentage</th>
<th>Hazards</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium lauryl sulfate</td>
<td>18.8 %</td>
<td>- Flammable solids (Category 2), H228</td>
</tr>
<tr>
<td>151-21-3</td>
<td></td>
<td>- Acute toxicity (Category 4), H332</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Acute toxicity (Category 4), H302</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Skin corrosion/irritation (Category 2), H315</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Serious eye damage/eye irritation (Category 1), H318</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Specific target organ toxicity - Single exposure (Category 3), H335</td>
</tr>
<tr>
<td>Calcium carboxymethyl cellulose</td>
<td>10.8 %</td>
<td></td>
</tr>
<tr>
<td>9050-04-8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactose monohydrate</td>
<td>8.4 %</td>
<td></td>
</tr>
<tr>
<td>10039-26-6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*For the full text of the ‘Hazard statements’ mentioned in this Section, see Section 16.*

### SECTION 4: First aid measures

#### 4.1. Description of first aid measures

**Eye contact**
- rinse with tap water for 20 minutes - open eyelids forcibly

**Skin contact**
- when in contact with the skin, clean with soap and water

**Inhalation**
- in the event of symptoms get medical treatment

#### 4.2. Most important symptoms and effects, both acute and delayed

**Note**
- no information available

#### 4.3. Indication of any immediate medical attention and special treatment needed

**Note to physician**
- treat symptomatically

### SECTION 5: Firefighting measures

#### 5.1. Extinguishing media

**Suitable extinguishing media**
- adapt extinguishing media to surrounding fire conditions
  - water spray jet, dry powder, foam, carbon dioxide

**Flash point (liquid)**
- not applicable

#### 5.2. Special hazards arising from the substance or mixture

**Specific hazards**
- formation of toxic and corrosive combustion gases (nitrous oxide, hydrogen chloride) possible

#### 5.3. Advice for firefighters

**Protection of fire-fighters**
- precipitate gases/vapours/mists with water spray
**SECTION 6: Accidental release measures**

6.1. Personal precautions, protective equipment and emergency procedures

- Personal precautions - avoid exposure

6.2. Environmental precautions

- Environmental protection - do not allow to enter drains or waterways

6.3. Methods and material for containment and cleaning up

- Methods for cleaning up - take up mechanically and dispose of

**SECTION 7: Handling and storage**

7.1. Precautions for safe handling

- Technical measures - provide suitable exhaust ventilation at the processing machines
- Suitable materials - stainless steel, aluminium, enamel, glass

7.2. Conditions for safe storage, including any incompatibilities

- Storage conditions - below 30 °C
  - protected from light and humidity
- Validity - see expiry date on the label
- Packaging materials - polyethylene bag in metal drum
  - tightly closing
  - blister packages

**SECTION 8: Exposure controls/personal protection**

8.1. Control parameters

- Threshold value (Roche) air - IOEL (Internal Occupational Exposure Limit): 0.001 mg/m³

8.2. Exposure controls

- General protective and hygiene measures - instruction of employees recommended
- Respiratory protection - Respiratory protection is recommended as a precaution to minimize exposure. Effective engineering controls are considered to be the primary means to control worker exposure. Respiratory protection should not substitute for feasible engineering controls.
  - respirator protection not necessary during normal operations
- Hand protection - protective gloves (eg made of neoprene, nitrile or butyl rubber)
**ALECENSA® Capsules (150 mg)**

**Eye protection**
- safety glasses

*1 referring to: Alectinib

**SECTION 9: Physical and chemical properties**

**9.1. Information on basic physical and chemical properties**
- **Color**: white to yellow-white
- **Form**: capsules

**9.2. Other information**
- **Note**: no information available

**SECTION 10: Stability and reactivity**

**10.1. Reactivity**
- **Note**: no information available

**10.2. Chemical stability**
- **Stability**: stable under the conditions mentioned in chapter 7

**10.3. Possibility of hazardous reactions**
- **Note**: no information available

**10.4. Conditions to avoid**
- **Conditions to avoid**: temperatures above 100 °C
  - humidity
  - light

**10.5. Incompatible materials**
- **Note**: no information available

**10.6. Hazardous decomposition products**
- **Note**: no information available
**SECTION 11: Toxicological information**

11.1. Information on toxicological effects

**Acute toxicity**
- LD$_0$ 2'000 mg/kg (oral, rat) *1
- LD$_{50}$ 1'427 mg/kg (oral, rat) (OECD No. 401) *2
- LD$_{50}$ > 2'000 mg/kg (dermal, rabbit) *2

**Local effects**
- eye: causes serious eye damage (rabbit; OECD No. 405) *2
- skin: irritant (rabbit; OECD No. 404) *2
- mucous membranes: irritant *2

**Sensitization**
- possibly photosensitising (OECD No. 432) *1

**Mutagenicity**
- negative, both with and without metabolic activation (Ames test) *1
- test system in vivo; OECD No. 474 (Micronucleus Test), oral; NOEL = 200 mg/kg/d; an increased number of micronucleated immature erythrocytes was seen at doses higher than 500 mg/kg/d *1
- does not induce chromosomal aberrations in vitro (in vitro test system; OECD No. 473 (Mammalian Cytogenic Test)); a slight increase in polyploid cells was seen at the dose of 10 mcg/ml *1
- positive (OECD No. 487 (In vitro Mammalian Cell Micronucleus Test)) *1

**Carcinogenicity**
- no information available

**Reproductive toxicity**
- NOAEL = 3 mg/kg/d (oral, rat, female, 11 d) *1
- decrease in fetal weight *1
- visceral anomaly ratio increased *1
- retarded ossification *1
- increased frequency in skeletal variations *1

**STOT—single exposure**
- no information available

**STOT—repeated exposure**
- no information available

**Aspiration hazard**
- no information available

**Note**
- possible side effects: leukopenia, neutropenia, thrombocytopenia, anemia, rash, nausea, increase of weight, headache *1

**Potential Health Effects**
- Exposure: Inhalation, Ingestion, Skin contact, Eye contact
- Carcinogenicity: not listed by NTP, IARC or OSHA

*1 referring to: Alectinib
*2 referring to: Sodium lauryl sulfate
### SECTION 12: Ecological information

#### 12.1. Toxicity

**Ecotoxicity**
- Moderately toxic for algae (Pseudokirchneriella subcapitata)
  - EC$_{50}$ (72 h) > 10 mg/l (nominal concentration)
  - NOEC (72 h) 10 mg/l (nominal concentration)
  - NOErC (72 h) 10 mg/l (nominal concentration)
  - (OECD No. 201)

- Barely toxic for planktonic crustaceans (Daphnia magna)
  - EC$_{50}$ (48 h) > 100 mg/l (nominal concentration)
  - NOEC (48 h) 100 mg/l (nominal concentration)
  - (OECD No. 202)

- Moderately toxic for fish (zebrafish)
  - LC$_{50}$ (96 h) > 10 mg/l (nominal concentration)
  - (OECD No. 203)

- Barely inhibitory on aerobic bacterial respiration (activated sludge)
  - NOEC (3 h) 1000 mg/l
  - (Activated Sludge Respir. Inhib. Test, OECD No. 209)

#### 12.2. Persistence and degradability

**Ready biodegradability**
- Not readily biodegradable
  - 0 % BOD/ThOD, 28 d
  - (Manometric Respirometry Test, OECD No. 301 F)

#### 12.3. Bioaccumulative potential

**Note**
- No information available

#### 12.4. Mobility in soil

**Note**
- No information available

#### 12.5. Results of PBT and vPvB assessment

**PBT/vPvB**
- Not PBT, not vPvB

#### 12.6. Other adverse effects

**Note**
- No information available

**Note**
- Referring to: Alectinib hydrochloride

---

*3 referring to:* Alectinib hydrochloride
SECTION 13: Disposal considerations

13.1. Waste treatment methods

Waste from residues - return to supplier or hand over to authorized disposal company
- observe local/national regulations regarding waste disposal
- incinerate in qualified installation with flue gas scrubbing
- DO NOT FLUSH unused medications or POUR them down a sink or drain. If available in your area, use takeback programs run by household hazardous waste collection programs or community pharmacies to dispose of unused and expired medicines. If you don’t have access to a takeback program, dispose of these medicines in the household trash by removing them from their original containers and mixing them with an undesirable substance, such as used coffee grounds or kitty litter.

SECTION 14: Transport information

Note - not classified as Dangerous Good according to the Dangerous Goods Regulations, proper shipping name non-regulated

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

TSCA Status - FDA Exemption - not on inventory

Reporting Requirements - The United States Environmental Protection Agency (USEPA) has not established a Reportable Quantity (RQ) for releases of this material.
- In New Jersey, report all releases, which are likely to endanger the public health, harm the environment or cause a complaint, to the NJDEPE Hotline and to local officials.
- State and local regulations vary and may impose additional reporting requirements.

SECTION 16: Other information

Safety-lab number - BS10767
- BS10498

Date: 16.5.17/LS (SEISMO) Replacing edition of: 18.4.17 Page: 8/9
Full text of H-Statements referred to under section 3

H228 Flammable solid.
H302 Harmful if swallowed.
H315 Causes skin irritation.
H318 Causes serious eye damage.
H332 Harmful if inhaled.
H335 May cause respiratory irritation.
H341 Suspected of causing genetic defects.
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373 May cause damage to organs through prolonged or repeated exposure.

USH003 May form combustible dust concentrations in the air

Note - Please note this Safety Data Sheet for the bulk product does not apply for the finished, packaged medicinal product intended for the final user.

Edition documentation - changes from previous version in sections 7, 9

**3 referring to:** Alectinib hydrochloride